Sonoma Pharmaceuticals (NASDAQ: SNOA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Risk & Volatility

Sonoma Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 4.75, suggesting that its share price is 375% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sonoma Pharmaceuticals and Syndax Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals 0 0 1 0 3.00
Syndax Pharmaceuticals 0 0 10 0 3.00

Sonoma Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 76.37%. Syndax Pharmaceuticals has a consensus price target of $24.88, suggesting a potential upside of 104.23%. Given Syndax Pharmaceuticals’ higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.

Valuation and Earnings

This table compares Sonoma Pharmaceuticals and Syndax Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sonoma Pharmaceuticals $14.02 million 1.74 -$12.55 million $1.99 2.85
Syndax Pharmaceuticals $1.22 million 221.83 -$53.19 million ($2.84) -4.29

Sonoma Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

9.8% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 70.7% of Syndax Pharmaceuticals shares are held by institutional investors. 13.3% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 24.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Sonoma Pharmaceuticals and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals 54.36% -44.24% -36.04%
Syndax Pharmaceuticals -4,294.59% -58.23% -45.65%

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company‚Äôs product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.